ATE288431T1 - Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum - Google Patents
Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstumInfo
- Publication number
- ATE288431T1 ATE288431T1 AT01938484T AT01938484T ATE288431T1 AT E288431 T1 ATE288431 T1 AT E288431T1 AT 01938484 T AT01938484 T AT 01938484T AT 01938484 T AT01938484 T AT 01938484T AT E288431 T1 ATE288431 T1 AT E288431T1
- Authority
- AT
- Austria
- Prior art keywords
- bizyclic
- derivatives
- substituted
- treatment
- cell growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21313600P | 2000-06-22 | 2000-06-22 | |
| PCT/IB2001/001046 WO2001098277A2 (en) | 2000-06-22 | 2001-06-14 | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE288431T1 true ATE288431T1 (de) | 2005-02-15 |
Family
ID=22793862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01938484T ATE288431T1 (de) | 2000-06-22 | 2001-06-14 | Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum |
Country Status (43)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| EP1117653B1 (en) | 1998-10-01 | 2003-02-05 | AstraZeneca AB | Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases |
| EE200200710A (et) * | 2000-06-22 | 2004-06-15 | Pfizer Products Inc. | Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks |
| KR100861486B1 (ko) * | 2001-02-21 | 2008-10-02 | 미쓰비시 타나베 파마 코퍼레이션 | 퀴나졸린 유도체 |
| US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
| MXPA04005157A (es) * | 2001-11-30 | 2004-08-11 | Pfizer Prod Inc | Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
| PL370858A1 (en) * | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| HUP0501069A2 (en) * | 2001-12-12 | 2006-06-28 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| AU2003291394B2 (en) | 2002-11-20 | 2009-06-25 | Array Biopharma, Inc | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| BR0317433A (pt) * | 2002-12-18 | 2005-11-16 | Pfizer Prod Inc | Derivados bicìclicos para o tratamento do crescimento celular anormal |
| JP2006512355A (ja) * | 2002-12-19 | 2006-04-13 | ファイザー・プロダクツ・インク | Ｅ−２−メトキシ−ｎ−（３−｛４−［３−メチル−４−（６−メチルピリジン−３−イルオキシ）−フェニルアミノ］−キナゾリン−６−イル｝−アリル）−アセトアミドの複合体、それらの製造方法および使用 |
| AU2004228460A1 (en) * | 2003-04-09 | 2004-10-21 | Pfizer Products Inc. | Processes for the preparation of N-((((pyridinyloxy) -phenylamino) quinazolinyl)- allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates |
| EP1636195A1 (en) * | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| CN1984660B (zh) * | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉 |
| AU2004257362A1 (en) * | 2003-07-15 | 2005-01-27 | National Research Council Of Canada | Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7452895B2 (en) * | 2003-08-14 | 2008-11-18 | Array Biopharma Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| BRPI0413745A (pt) * | 2003-08-18 | 2006-10-24 | Pfizer Prod Inc | horário mde dosagem para agentes anticancerìgenos erbb2 |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| EP2612853A1 (en) * | 2003-09-26 | 2013-07-10 | Exelixis Inc. | c-Met modulators and methods of use |
| MXPA06005024A (es) * | 2003-11-06 | 2006-07-06 | Pfizer Prod Inc | Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer. |
| EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
| US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
| EP1802341A1 (en) | 2004-07-16 | 2007-07-04 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| WO2006025490A1 (ja) * | 2004-09-01 | 2006-03-09 | Mitsubishi Pharma Corporation | 分子シャペロン機能調節剤 |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| EP1877444A2 (en) | 2005-04-26 | 2008-01-16 | Pfizer, Inc. | P-cadherin antibodies |
| EP1896451A2 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Bicyclic derivatives for the treatment of abnormal cell growth |
| CA2610661A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| EA201300320A1 (ru) | 2005-09-07 | 2014-02-28 | Эмджен Фримонт Инк. | Моноклональные антитела человека к киназе-1, подобной рецептору активина |
| ZA200804498B (en) | 2005-11-15 | 2009-07-29 | Array Biopharma Inc | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| GB0526552D0 (en) * | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| CA2651629A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| WO2008002039A1 (en) * | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| SG174774A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
| JP2010502743A (ja) * | 2006-09-11 | 2010-01-28 | キュリス，インコーポレイテッド | 抗増殖薬剤としての多機能性低分子 |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| JPWO2008072634A1 (ja) | 2006-12-12 | 2010-04-02 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
| US8715665B2 (en) | 2007-04-13 | 2014-05-06 | The General Hospital Corporation | Methods for treating cancer resistant to ErbB therapeutics |
| WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| TW200944528A (en) | 2008-03-12 | 2009-11-01 | Takeda Pharmaceutical | Fused heterocyclic compound |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
| TWI447108B (zh) | 2009-01-16 | 2014-08-01 | Exelixis Inc | Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP2473500A2 (en) | 2009-09-01 | 2012-07-11 | Pfizer Inc. | Benzimidazole derivatives |
| US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
| US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9056865B2 (en) | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2-derivatives as smoothened receptor modulators |
| EP2758402B9 (en) | 2011-09-22 | 2016-09-14 | Pfizer Inc | Pyrrolopyrimidine and purine derivatives |
| CN102872018B (zh) * | 2012-10-23 | 2015-07-15 | 广州市恒诺康医药科技有限公司 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| AP2016009530A0 (en) | 2014-04-30 | 2016-10-31 | Pfizer | Cycloalkyl-linked diheterocycle derivatives |
| KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| WO2017003668A1 (en) | 2015-07-01 | 2017-01-05 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| US10828305B2 (en) | 2016-03-01 | 2020-11-10 | Shanghai Pharmaceuticals Holding Co., Ltd. | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| ES2971927T3 (es) | 2018-09-18 | 2024-06-10 | Hoffmann La Roche | Derivados de quinazolina como agentes antitumorales |
| TW202345816A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW321649B (US20070244113A1-20071018-C00138.png) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| CN1161352C (zh) | 1998-10-08 | 2004-08-11 | 阿斯特拉曾尼卡有限公司 | 喹唑啉衍生物 |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| EE200200710A (et) * | 2000-06-22 | 2004-06-15 | Pfizer Products Inc. | Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks |
-
2001
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en active Application Filing
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active IP Right Cessation
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
-
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166L/no unknown
-
2005
- 2005-03-11 HK HK05102099A patent/HK1069576A1/xx not_active IP Right Cessation
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE288431T1 (de) | Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum | |
| DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE458731T1 (de) | Pyrimidin-derivate zur behandlung von anormalem zellwachstum | |
| DE60329123D1 (de) | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten | |
| ATE374196T1 (de) | Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
| DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
| DE60024649D1 (de) | Verbindungen für die behandlung von ischämie | |
| DE69927823D1 (de) | Hydrogel für die therapeutische behandlung von aneurysmas | |
| ATE345331T1 (de) | Verbindungen verwendbar für die behandlung von entzündungskrankheiten | |
| ATE304358T1 (de) | (s,s)-reboxetin zur behandlung von migränekopfschmerzen | |
| DE60325498D1 (de) | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen | |
| DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
| ATE286895T1 (de) | Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten | |
| DE60239218D1 (de) | Synergistische zusammensetzungen für die behandlung von saatgut | |
| DE60239558D1 (de) | Kombinationen für die behandlung von immun-entzündlichen erkrankungen | |
| DE60236218D1 (de) | CCR5 Antagonisten verwendbar für die Behandlung von Aids | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| DE60105614D1 (de) | Oxazinochinolone für die behandlung viraler infektionen | |
| DE60120990D1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1292591 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |